The present invention relates to novel compounds, in particular peptidic macrocyclic peptides, that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses comprising HA of the H1 subtype 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic 5 compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.